Discovery of XYD270 as a Potent, Selective, and Orally Efficacious BRD9 PROTAC for Cancer Therapy - PubMed
11 hours ago
- #BRD9 PROTAC
- #XYD270
- #Cancer Therapy
- Discovery of XYD270 as a potent, selective, and orally efficacious BRD9 PROTAC for cancer therapy.
- BRD9 is a promising therapeutic target in cancers like synovial sarcoma (SS) and acute myeloid leukemia (AML).
- XYD270 shows excellent degradation activity in HS-SY-II and MV4;11 cells with high potency.
- XYD270 exhibits robust antiproliferative activity in MV4;11 and HS-SY-II cells.
- In an MV4;11 xenograft model, XYD270 achieved significant tumor growth inhibition (54%).
- XYD270 is established as a promising BRD9 PROTAC with compelling preclinical efficacy in SS and AML.